Search results
- The non-proprietary name of a drug is the name accepted by a competent scientific body or authority, such as the USAN or BAN. The non-proprietary names of newer drugs are kept uniform by an agreement to use the Recommended International Nonproprietary Name (rINN) in all member countries of the World Health Organization (WHO).
pharmacologymentor.com › drug-nomenclature
People also ask
What is a non-proprietary name?
What is a non-proprietary name for a drug?
Can a drug have more than one non-proprietary name?
What is a proprietary name of a drug?
Mar 25, 2024 · Non-Proprietary Name. The non-proprietary name of a drug is the name accepted by a competent scientific body or authority, such as the USAN or BAN. The non-proprietary names of newer drugs are kept uniform by an agreement to use the Recommended International Nonproprietary Name (rINN) in all member countries of the World Health Organization (WHO).
Dec 15, 2023 · International Non-proprietary Names (INNs) are the standardized, generic names assigned to drugs by the World Health Organization (WHO). These unique, non-branded names aim to: Prevent confusion: INNs avoid the potential for confusion caused by brand names, which can vary depending on the country and manufacturer.
An international nonproprietary name (INN) is an official generic and nonproprietary name given to a pharmaceutical drug or an active ingredient. INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors.
Apr 13, 2021 · The World Health Organization assigns international nonproprietary names (INN), also known as common names, to compounds upon request from drug developers. Structures of INNs are publicly available and represent a source, albeit underused, to understand trends in drug research and development.
- Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, Armando A Genazz...
- 2021
Jan 17, 2017 · non-proprietary. attached to the core name of the drug with a hyphen. free of legal barriers that would restrict use of the suffix. Previously licensed biologics with names that do not meet the requirements of the Final Guidance will need to undergo name changes.
Jan 18, 2017 · 1 The Guidance defines “related biological product” as “a biological product submitted in a Biologics License Application (BLA) under section 351(a) of the Public Health Service Act (i.e., a stand-alone BLA) for which there is a previously licensed biological product submitted in a different section 351(a) BLA that contains a drug ...
Feb 21, 2023 · The USAN Council, the WHO’s International Nonproprietary Names (INN) expert group, and a medication’s manufacturer must agree on a generic name. The generic name selection process typically occurs in early phases of clinical trials. A generic name has a few defining elements, such as a common stem.
